Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 27 of 196
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

Ardelyx resubmits NDA for Xphozah to US FDA

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response